Bausch Health Companies Inc. (BHC): Price and Financial Metrics

Bausch Health Companies Inc. (BHC): $9.58

0.31 (-3.13%)

POWR Rating

Component Grades








BHC Price/Volume Stats

Current price $9.58 52-week high $10.15
Prev. close $9.89 52-week low $5.57
Day low $9.48 Volume 2,855,139
Day high $9.88 Avg. volume 2,581,430
50-day MA $8.32 Dividend yield N/A
200-day MA $8.02 Market Cap 3.50B

BHC Stock Price Chart Interactive Chart >


  • Growth is the dimension where BHC ranks best; there it ranks ahead of 99.57% of US stocks.
  • The strongest trend for BHC is in Growth, which has been heading up over the past 26 weeks.
  • BHC ranks lowest in Momentum; there it ranks in the 6th percentile.

BHC Stock Summary

  • BAUSCH HEALTH COMPANIES INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 2.14% of US listed stocks.
  • Price to trailing twelve month operating cash flow for BHC is currently 2.55, higher than only 7.68% of US stocks with positive operating cash flow.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -31.09 for BAUSCH HEALTH COMPANIES INC; that's greater than it is for only 0.89% of US stocks.
  • Stocks that are quantitatively similar to BHC, based on their financial statements, market capitalization, and price volatility, are RVNC, MRAI, CCLP, SOND, and AVAH.
  • BHC's SEC filings can be seen here. And to visit BAUSCH HEALTH COMPANIES INC's official web site, go to

BHC Valuation Summary

  • BHC's price/sales ratio is 0.3; this is 92.86% lower than that of the median Healthcare stock.
  • Over the past 243 months, BHC's price/sales ratio has gone down 4.3.

Below are key valuation metrics over time for BHC.

Stock Date P/S P/B P/E EV/EBIT
BHC 2023-12-29 0.3 -2.5 -3.0 45.3
BHC 2023-12-28 0.3 -2.5 -3.0 45.3
BHC 2023-12-27 0.3 -2.4 -2.9 45.1
BHC 2023-12-26 0.3 -2.4 -2.9 45.0
BHC 2023-12-22 0.3 -2.3 -2.8 44.9
BHC 2023-12-21 0.3 -2.3 -2.8 44.9

BHC Growth Metrics

    Its year over year net cashflow from operations growth rate is now at -28.85%.
  • Its year over year price growth rate is now at -66.36%.
  • The 3 year revenue growth rate now stands at -0.9%.
BHC's revenue has moved down $474,000,000 over the prior 33 months.

The table below shows BHC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8,127 -1,179 254
2022-06-30 8,192 648 43
2022-03-31 8,325 920 -407
2021-12-31 8,434 1,426 -948
2021-09-30 8,451 1,796 -1,170
2021-06-30 8,478 1,488 -1,287

BHC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BHC has a Quality Grade of C, ranking ahead of 53.93% of graded US stocks.
  • BHC's asset turnover comes in at 0.276 -- ranking 162nd of 680 Pharmaceutical Products stocks.
  • CCXI, NBY, and LLY are the stocks whose asset turnover ratios are most correlated with BHC.

The table below shows BHC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.276 0.714 -0.004
2021-03-31 0.259 0.714 0.006
2020-12-31 0.255 0.720 0.022
2020-09-30 0.250 0.721 -0.017
2020-06-30 0.252 0.725 -0.021
2020-03-31 0.265 0.729 -0.011

BHC Price Target

For more insight on analysts targets of BHC, see our BHC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.08 Average Broker Recommendation 1.62 (Moderate Buy)

Bausch Health Companies Inc. (BHC) Company Bio

Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.

BHC Latest News Stream

Event/Time News Detail
Loading, please wait...

BHC Latest Social Stream

Loading social stream, please wait...

View Full BHC Social Stream

Latest BHC News From Around the Web

Below are the latest news stories about BAUSCH HEALTH COMPANIES INC that investors may wish to consider to help them evaluate BHC as an investment opportunity.

Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal

Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.

Yahoo | December 22, 2023

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis

Trial Meets Both Primary and Key Secondary Endpoints LAVAL, QC / ACCESSWIRE / December 21, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced positive topline results from the Company's Phase ...

Yahoo | December 21, 2023

Are Medical Stocks Lagging Bausch Health (BHC) This Year?

Here is how Bausch Health (BHC) and Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have performed compared to their sector so far this year.

Yahoo | December 18, 2023

DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan

LAVAL, QC / ACCESSWIRE / December 18, 2023 / Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), ("Bausch Health" or the "Company") today announced that DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene), ...

Yahoo | December 18, 2023

Implied Volatility Surging for On Bausch Health Companies (BHC) Stock Options

Investors need to pay close attention to Bausch Health Companies (BHC) stock based on the movements in the options market lately.

Yahoo | December 13, 2023

Read More 'BHC' Stories Here

BHC Price Returns

1-mo 20.96%
3-mo 34.36%
6-mo 14.59%
1-year 4.59%
3-year -70.94%
5-year -59.34%
YTD 19.45%
2023 27.71%
2022 -77.25%
2021 32.74%
2020 -30.48%
2019 61.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!